Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.88 |
| ▸ | HMGCR | P04035 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | ACLY | P53396 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | SLC13A5 | Q86YT5 | 4/20 | 0.41 |
| ▸ | CPT2 | P23786 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL37496 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL365960 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL372189 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL372671 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL372535 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL8146438 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL13684439 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL20917177 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL21753855 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL372698 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110987553-B | Erythrocyte treatment reagent and application thereof | 中山市创艺生化工程有限公司 | 2022-06-24 | — | — | CN | claimed |
| CN-110987553-A | Erythrocyte treatment reagent and application thereof | 中山市创艺生化工程有限公司 | 2020-04-10 | — | — | CN | claimed |
| CN-117965685-A | Sample preservation solution and preparation method thereof | 深圳乐土生物科技有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-116688096-A | Endoplasmic reticulum stress as a predictive tool in cancer therapy and combination therapy for cancer treatment | 免疫系统密钥有限公司 | 2023-09-05 | — | — | CN | disclosed |
| CN-110987553-B | Erythrocyte treatment reagent and application thereof | 中山市创艺生化工程有限公司 | 2022-06-24 | — | — | CN | disclosed |
| CN-110987553-A | Erythrocyte treatment reagent and application thereof | 中山市创艺生化工程有限公司 | 2020-04-10 | — | — | CN | disclosed |
| US-20140296490-A1 | HIGHLY GALACTOSYLATED ANTIBODIES | LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES (FR) | 2014-10-02 | — | — | US | disclosed |
| WO-2012044409-A1 | METHOD FOR CONTROLLING MICROBIAL BIOFILM IN AQUEOUS SYSTEMS | GENERAL ELECTRIC COMPANY (US) | 2012-04-05 | — | — | WO | disclosed |
| US-8114804-B2 | Self-deagglomerating suspensions of titanium (IV) oxides and methods for making them | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-02-14 | — | — | US | disclosed |
| US-7998453-B2 | Suspensions of titanium (IV) oxide particles and process for their production | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-08-16 | — | — | US | disclosed |
| US-7887779-B2 | single step vigorous mixing, alcohol, titanium alkoxide, and activator such as water, ammonium hydroxide, sodium hydroxide, sodium pyrophosphate, potassium pyrophosphate, sodium citrate, diammonium hydrogen phosphate, heating mixture | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-02-15 | — | — | US | disclosed |
| CN-100386076-C | Cardiovascular pharmaceutical formulation, preparation method and uses | LI LIU (CN) | 2008-05-07 | — | — | CN | disclosed |
| CN-1839821-A | Cardiovascular pharmaceutical formulation, preparation method and uses | LIU LI (CN) | 2006-10-04 | — | — | CN | disclosed |